| Literature DB >> 33209448 |
Zhangwei Qiu1, Wei Dai2, Madiha-Zahra Syeda3, Liujian Ouyang3,4, Jie Lin1, Laifang Sun5, Zhefeng Leng1, Xinmiao Chen1, Xiaoting Xu1, Yaxin Zhao6, Binyu Ying7, Xian Shen6, Songmin Ying3, Yuanrong Dai1.
Abstract
Entities:
Year: 2020 PMID: 33209448 PMCID: PMC7656416 DOI: 10.21037/jtd-20-1861
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Clinical features of patients with COVID-19
| Clinical features | All patients (n=64) | Uncomp. (n=3) | Mild (n=57) | Severe (n=4) | P value (mild | P value (severe | P value (severe |
|---|---|---|---|---|---|---|---|
| Age (years), median [range] | 48.5 [10–77] | 19 [10–32] | 49 [20–77] | 44 [41–49] | – | – | 0.11 |
| Male, (%) | 38/64 (59.4) | 0/3 (0.0) | 34/57 (59.6) | 4/4 (100.0) | 0.076 | 0.029 | 0.29 |
| Family onset, (%) | 25/64 (39.1) | - | - | - | – | – | – |
| Symptoms, (%) | |||||||
| None | 6/64 (9.4) | 1/3 (33.3) | 5/57 (8.8) | 0/4 (0.0) | 0.28 | 0.43 | – |
| Fever | 46/64 (71.9) | 1/3 (33.3) | 41/57 (71.9) | 4/4 (100.0) | 0.21 | 0.14 | 0.57 |
| Cough | 41/64 (64.1) | 0/3 (0.0) | 39/57 (68.4) | 2/4 (50.0) | 0.039 | 0.43 | 0.59 |
| Sputum production | 23/64 (35.9) | 0/3 (0.0) | 21/57 (36.8) | 2/4 (50.0) | 0.55 | 0.43 | 0.63 |
| Myalgia | 15/64 (23.4) | 1/3 (33.3) | 12/57 (21.1) | 2/4 (50.0) | 0.53 | – | 0.22 |
| Nausea/vomiting | 2/64 (3.1) | 0/3 (0.0) | 2/57 (3.5) | 0/4 (0.0) | – | – | – |
| Abdominal pain/diarrhea | 7/64 (10.9) | 0/3 (0.0) | 7/57 (12.3) | 0/4 (0.0) | – | – | – |
| Conjunctival congestion | 1/64 (1.6) | 0/3 (0.0) | 1/57 (1.8) | 0/4 (0.0) | – | – | – |
| Laboratory findings | |||||||
| White blood cell (×109/L) | |||||||
| Mean (SD) | 4.77 (1.23) | 5.70 (2.21) | 4.67 (0.21) | 5.49 (0.60) | 0.16 | 0.86 | 0.18 |
| <4, (%) | 16/64 (25.0) | 1/3 (33.3) | 15/57 (26.3) | 0/4 (0.0) | – | 0.43 | 0.56 |
| Lymphocyte (×109/L) | |||||||
| Mean (SD) | 1.36 (0.44) | 1.86 (0.76) | 1,35 (0.41) | 1.09 (0.39) | 0.51 | 0.14 | 0.22 |
| <1.1, (%) | 17/64 (26.6) | 0/3 (0.0) | 15/57 (26.3) | 2/4(50.0) | 0.57 | 0.43 | 0.31 |
| Eosinophil (×109/L) | |||||||
| Mean (SD) | 0.055 (0.062) | 0.063 (0.051) | 0.057 (0.064) | 0.028 (0.045) | 0.87 | 0.38 | 0.37 |
| <0.02, (%) | 23/64 (35.9) | 0/3 (0.0) | 20/57 (35.1) | 3/4 (75.0) | 0.54 | 0.14 | 0.15 |
| CRP (mg/L) | |||||||
| Mean (SD) | 23.89 (32.71) | 2.32 (3.39) | 22.48 (30.13) | 60.22 (57.09) | 0.051 | 0.057 | 0.068 |
| >8, (%) | 36/64 (56.3) | 0/3 (0.0) | 32/57 (56.1) | 4/4 (100.0) | 0.096 | 0.029 | 0.14 |
| D-Dimer (μg/mL) | 23/61 (37.7) | 0/2 (0.0) | 20/55 (36.4) | 3/4 (75.0) | 0.54 | 0.40 | 0.32 |
| CT findings | |||||||
| Left lung involvement only, (%) | 4/64 (6.3) | 0/3 (0.0) | 4/57 (7.0) | 0/4 (0.0) | – | – | – |
| Right lung involvement only, (%) | 7/64 (10.9) | 0/3 (0.0) | 7/57 (12.3) | 0/4 (0.0) | – | – | – |
| Bilateral involvement, (%) | 50/64 (78.1) | 0/3 (0.0) | 46/57 (80.7) | 4/4 (100.0) | 0.011 | 0.029 | – |
| CT score, mean (SD) | 24.9 (22.2) | 0 (0.0) | 22.2 (16.24) | 47.8 (2.90) | – | – | 0.0028 |
| Medical therapies, (%) | |||||||
| Interferon | 49/64 (76.6) | 3/3 (100.0) | 45/57 (78.9) | 1/4 (25.0) | – | 0.14 | 0.043 |
| Antiviral agents | 58/64 (90.6) | 2/3 (66.7) | 53/57 (93.0) | 3/4 (75.0) | 0.23 | – | 0.30 |
| Corticosteroid | 4/64 (6.3) | 0/3 (0.0) | 1/57 (1.8) | 3/4 (75.0) | – | 0.14 | – |
| Antibiotics | 11/64 (17.2) | 0/3 (0.0) | 9/57 (15.8) | 2/4 (50.0) | – | 0.43 | 0.15 |
| Oxygen therapy, (%) | 62/64 (96.9) | 3/3 (100.0) | 55/57 (96.5) | 4/4 (100.0) | – | – | – |
| Outcomes cure, (%) | 64/64 (100.0) | 3/3 (100.0) | 57/57 (100.0) | 4/4 (100.0) | – | – | – |
Data are presented as median (range), mean (standard deviation) or n/N (%), where N is the total number of patients. P values comparing uncomp., mild, and severe respectively are from χ2, Fisher’s exact test, independent-samples t-test, or one-way ANOVA. Uncomp., uncomplicated illness; mild, mild pneumonia; severe, severe pneumonia.
Figure 1Demographic and clinical features of patients with COVID-19. (A) A 5th-generation case. P1 (G2), who had never contacted with wildlife or Huanan Seafood Market, came back from Wuhan and visited his friend (P2, G3) on Jan 19, the next day after which P1 (G2) developed fever and diagnosed COVID-19 On Jan 28, 2020. On Jan 31, 2020, 12 days after the visit, P2 was also diagnosed positive for COVID-19 on Feb 1 after having fever for 1-day. Later, P2’s daughter-in-law (P3, G4) and son (P4, G4) also developed symptoms and were confirmed on Feb 3 and Feb 7, 2020, respectively. During this period, Patient 4 contacted his hairstylist (P5, G5) on Jan 29, and Jan 31, who developed fever on Feb 9 and then finally was laboratory-confirmed for COVID-19 on Feb 10, 2020. (B) 9-member cluster from a 12-member family, originated from a local epidemic area (Intime Mall). Index patient in this family cluster worked at Intime Mall and lived with her husband and son in Lucheng District. The couple and their son traveled to their hometown in Wencheng District on Jan 23, 2020, and repeatedly visited all of their relatives after that. 8 days later, the index patient’s father developed fever and diagnosed COVID-19 on Feb 2, 2020. One of her sister-in-law developed fever on Feb 3, 2020, and got diagnosed with COVID-19 the following day. The index patient felt no symptoms until she finally developed fever on Feb 5, 2020 and then laboratory-confirmed COVID-19, on the same day. Afterwards, all of the remaining 9 members of the family underwent SARS-CoV-2 RNA detection and 6 were confirmed positive, among whom 4 were asymptomatic. Although 2 patients of this family cluster were admitted in another hospital, we obtained their information by the detailed description of their relatives in our hospital. *, G: generation; **, dates refer to the date of diagnosis. Patients were grouped into three categories as per WHO interim guidance. Uncomp., uncomplicated illness; mild, mild pneumonia; severe, severe pneumonia. (C) Patients with abnormal lymphocyte count, eosinophil count and CRP of different groups were analyzed. (D) Neutrophil-to-lymphocyte ratio was compared among three groups. (E) Comparison of CT score was made among two groups with pneumonia.